Top

Published in:

01-03-2016 | Original Article

Expression of CDC5L is associated with tumor progression in gliomas

Authors: Wenjuan Chen, Li Zhang, Yan Wang, Jie Sun, Donglin Wang, Shaochen Fan, Na Ban, Junya Zhu, Bin Ji, Yuchan Wang

Published in: Tumor Biology | Issue 3/2016

Abstract

Cell division cycle 5-like (CDC5L) protein is a cell cycle regulator of the G₂/M transition and has been reported to participate in the catalytic step of pre-messenger RNA (mRNA) splicing and DNA damage repair. Recently, it was also found to act as a candidate oncogene in osteosarcoma and cervical tumors. However, the role of CDC5L expression in tumor biology was still unclear. Here, we analyzed the expression and clinical significance of CDC5L in gliomas. The expression of CDC5L in fresh glioma tissues and paraffin-embedded slices was evaluated by western blot and immunohistochemistry, respectively. We found that CDC5L was highly expressed in glioma tissues. The expression of CDC5L was significantly associated with glioma pathology grade and Ki-67 expression. Univariate and multivariate analyses showed that high CDC5L expression was an independent prognostic factor for glioma patients’ survival. To determine whether CDC5L could regulate the proliferation of glioma cells, we transfected glioma cells with interfering RNA target CDC5L, then investigated cell proliferation with cell counting kit (CCK)-8, flow cytometry assays and colony formation analyses. Our results indicated that knockdown of CDC5L would inhibit proliferation of glioma cells. Besides, reduced expression of CDC5L could induce the apoptosis of glioma cells. These findings suggested that CDC5L might play an important role in glioma and thus be a promising therapeutic target of glioma.

Bauer R, Kaiser M, Stoll E. A computational model incorporating neural stem cell dynamics reproduces glioma incidence across the lifespan in the human population. PLoS One. 2014;9(11):e111219. doi:10.1371/journal.pone.0111219.CrossRefPubMedPubMedCentral

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N. Antiangiogenic therapy for high-grade glioma. Cochrane Database Syst Rev. 2014;9:CD008218. doi:10.1002/14651858.CD008218.pub3.

Wang X, Zhao HY, Zhang FC, Sun Y, Xiong ZY, Jiang XB. Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review. Cancer Investig. 2014;32(9):451–7. doi:10.3109/07357907.2014.958234.CrossRef

Omar AI. Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastoma. J Vis Exp. 2014;92:e51638. doi:10.3791/51638.

Mrugala MM. Advances and challenges in the treatment of glioblastoma: a clinician’s perspective. Discov Med. 2013;15(83):221–30.PubMed

Sherr CJ. Cancer cell cycles. Science. 1996;274(5293):1672–7.CrossRefPubMed

Turowski P, Franckhauser C, Morris MC, Vaglio P, Fernandez A, Lamb NJ. Functional cdc25C dual-specificity phosphatase is required for S-phase entry in human cells. Mol Biol Cell. 2003;14(7):2984–98. doi:10.1091/mbc.E02-08-0515.CrossRefPubMedPubMedCentral

Bernstein HS, Coughlin SR. Pombe Cdc5-related protein. A putative human transcription factor implicated in mitogen-activated signaling. J Biol Chem. 1997;272(9):5833–7.CrossRefPubMed

Neubauer G, King A, Rappsilber J, Calvio C, Watson M, Ajuh P, et al. Mass spectrometry and EST-database searching allows characterization of the multi-protein spliceosome complex. Nat Genet. 1998;20(1):46–50. doi:10.1038/1700.CrossRefPubMed

10.

Ohi R, Feoktistova A, McCann S, Valentine V, Look AT, Lipsick JS, et al. Myb-related Schizosaccharomyces pombe cdc5p is structurally and functionally conserved in eukaryotes. Mol Cell Biol. 1998;18(7):4097–108.CrossRefPubMedPubMedCentral

11.

Ajuh P, Kuster B, Panov K, Zomerdijk JC, Mann M, Lamond AI. Functional analysis of the human CDC5L complex and identification of its components by mass spectrometry. EMBO J. 2000;19(23):6569–81. doi:10.1093/emboj/19.23.6569.CrossRefPubMedPubMedCentral

12.

Ajuh P, Lamond AI. Identification of peptide inhibitors of pre-mRNA splicing derived from the essential interaction domains of CDC5L and PLRG1. Nucleic Acids Res. 2003;31(21):6104–16.CrossRefPubMedPubMedCentral

13.

Ajuh P, Sleeman J, Chusainow J, Lamond AI. A direct interaction between the carboxyl-terminal region of CDC5L and the WD40 domain of PLRG1 is essential for pre-mRNA splicing. J Biol Chem. 2001;276(45):42370–81. doi:10.1074/jbc.M105453200.CrossRefPubMed

14.

Burns CG, Ohi R, Krainer AR, Gould KL. Evidence that Myb-related CDC5 proteins are required for pre-mRNA splicing. Proc Natl Acad Sci U S A. 1999;96(24):13789–94.CrossRefPubMedPubMedCentral

15.

Grote M, Wolf E, Will CL, Lemm I, Agafonov DE, Schomburg A, et al. Molecular architecture of the human Prp19/CDC5L complex. Mol Cell Biol. 2010;30(9):2105–19. doi:10.1128/MCB.01505-09.CrossRefPubMedPubMedCentral

16.

Bernstein HS, Coughlin SR. A mammalian homolog of fission yeast Cdc5 regulates G2 progression and mitotic entry. J Biol Chem. 1998;273(8):4666–71.CrossRefPubMed

17.

Nasmyth K, Nurse P. Cell division cycle mutants altered in DNA replication and mitosis in the fission yeast Schizosaccharomyces pombe. Mol Gen Genet. 1981;182(1):119–24.CrossRefPubMed

18.

Ohi R, McCollum D, Hirani B, Den Haese GJ, Zhang X, Burke JD, et al. The Schizosaccharomyces pombe cdc5+ gene encodes an essential protein with homology to c-Myb. EMBO J. 1994;13(2):471–83.PubMedPubMedCentral

19.

Mu R, Wang YB, Wu M, Yang Y, Song W, Li T, et al. Depletion of pre-mRNA splicing factor Cdc5L inhibits mitotic progression and triggers mitotic catastrophe. Cell Death Dis. 2014;5:e1151. doi:10.1038/cddis.2014.117.CrossRefPubMedPubMedCentral

20.

Lu XY, Lu Y, Zhao YJ, Jaeweon K, Kang J, Xiao-Nan L, et al. Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma. Mol Cancer Res. 2008;6(6):937–46. doi:10.1158/1541-7786.MCR-07-2115.CrossRefPubMedPubMedCentral

21.

Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol. 2013;15 Suppl 2:ii1–56. doi:10.1093/neuonc/not151.CrossRefPubMedPubMedCentral

22.

Auffinger B, Thaci B, Nigam P, Rincon E, Cheng Y, Lesniak MS. New therapeutic approaches for malignant glioma: in search of the Rosetta stone. F1000 Med Rep. 2012;4:18. doi:10.3410/M4-18.CrossRefPubMedPubMedCentral

23.

Wang H, Xu T, Jiang Y, Xu H, Yan Y, Fu D, et al. The challenges and the promise of molecular targeted therapy in malignant gliomas. Neoplasia. 2015;17(3):239–55. doi:10.1016/j.neo.2015.02.002.CrossRefPubMedPubMedCentral

24.

Uchida F, Uzawa K, Kasamatsu A, Takatori H, Sakamoto Y, Ogawara K, et al. Overexpression of cell cycle regulator CDCA3 promotes oral cancer progression by enhancing cell proliferation with prevention of G1 phase arrest. BMC Cancer. 2012;12:321. doi:10.1186/1471-2407-12-321.CrossRefPubMedPubMedCentral

25.

Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer. 2000;88(12):2887.CrossRefPubMed

26.

Zhang N, Kaur R, Akhter S, Legerski RJ. Cdc5L interacts with ATR and is required for the S-phase cell-cycle checkpoint. EMBO Rep. 2009;10(9):1029–35. doi:10.1038/embor.2009.122.CrossRefPubMedPubMedCentral

27.

Martin JW, Chilton-MacNeill S, Koti M, van Wijnen AJ, Squire JA, Zielenska M. Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma. PLoS One. 2014;9(5):e95843. doi:10.1371/journal.pone.0095843.CrossRefPubMedPubMedCentral

28.

Liu H, Schmitz JC, Wei J, Cao S, Beumer JH, Strychor S, et al. Clove extract inhibits tumor growth and promotes cell cycle arrest and apoptosis. Oncol Res. 2014;21(5):247–59. doi:10.3727/096504014X13946388748910.CrossRefPubMedPubMedCentral

29.

Xu MY, Kim YS. Antitumor activity of glycyrol via induction of cell cycle arrest, apoptosis and defective autophagy. Food Chem Toxicol. 2014;74:311–9. doi:10.1016/j.fct.2014.10.023.CrossRefPubMed

Title: Expression of CDC5L is associated with tumor progression in gliomas
Authors: Wenjuan Chen
Li Zhang
Yan Wang
Jie Sun
Donglin Wang
Shaochen Fan
Na Ban
Junya Zhu
Bin Ji
Yuchan Wang
Publication date: 01-03-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 3/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4088-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

The vascular delta-like ligand-4 (DLL4)-Notch4 signaling correlates with angiogenesis in primary glioblastoma: an immunohistochemical study

Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer

The potential role of the NEK6, AURKA, AURKB, and PAK1 genes in adenomatous colorectal polyps and colorectal adenocarcinoma

Decreased expression of p27 is associated with malignant transformation and extrathyroidal extension in papillary thyroid carcinoma

Comprehensive profiling of biological processes reveals two major prognostic subtypes in breast cancer

An integrative transcriptomic analysis reveals p53 regulated miRNA, mRNA, and lncRNA networks in nasopharyngeal carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer